CELLnTEC: Website to improve access to advanced cell culture solutions Verified listing

Monday, July 20, 2026 @ 12:00 am

The new digital platform reinforces CELLnTEC’s positioning as the pioneer in chemically defined, animal-free tissue culture and a leader in epithelial and skin tissue engineering

CELLnTEC Advanced Cell Systems AG, a Swiss life science company specializing in precision cell culture technologies, today announced the launch of its new website.

The new website reflects CELLnTEC’s leadership position in chemically defined, animal-free tissue culture, with a focus on enabling robust, reproducible, and scalable workflows for 2D & 3D cell culture, tissue engineering, stem cell research, advanced in vitro test model and New Approach Methodologies (NAMs), and ATMP-development.

For more than two decades, CELLnTEC has developed specialty media and cell culture systems designed to support high-performance cell and tissue culture. The new digital platform makes it easier for users to explore CELLnTEC’s solutions by product type, cell type, and application area, helping researchers identify appropriate tools for epithelial proliferation, differentiation, co-culture, 3D models, or barrier-forming tissues, and translational workflows.

“Our new website is more than a refreshed digital presence. It is a practical resource for the scientific and industrial communities we serve,” said Anand David, Head of Scientific Marketing at CELLnTEC. “By improving access to product information, protocols, application knowledge, and distributor resources, we are making it easier for researchers and developers to select chemically defined, animal-free culture systems that support reproducibility, biological relevance, and future clinical or industrial translation.”

You may also be interested in

Swiss Biotech Report 2026: Strong performance with new records in revenues and investments in privately funded companies

Total revenues reached a record CHF 7.5 billion in 2025 (CHF 7.2 billion in 2024) with more companies maturing to the commercial stage and a continuously growing demand for specialized CDMO services. Funding increased by 2.1% to CHF 2.6 billion. In a notable shift, investments in privately funded companies achieved a record CHF 1.15 billion – an increase of 38% compared to 2024, and a record 45%
May 5, 2026

Fraud campaigns without connection to the Swiss Biotech Association or the Swiss Biotech Day

We are tracking and escalating fraud campaigns targeting Swiss Biotech Association members and Swiss Biotech Day participants. Multiple fraudulent domains and Gmail accounts have already been identified and reported to their registrars and hosts; several have been taken down, but new ones continue to appear. Please read this alert carefully and share it within your organization.
April 16, 2026

Pharvaris: Publication summarizes evidence supporting bradykinin B2 receptor as therapeutic target

Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases
July 22, 2026

Preclina: First humanized mouse model for pulmonary fibrosis free of 'GvHD'

HSC-based humanized mouse model of pulmonary fibrosis achieves stable multilineage human immune engraftment without graft-versus-host disease Nintedanib treatment confirms clinically consistent drug response, validating the model for evaluation of human-specific biologics and cell therapies International patent filed under the Patent Cooperation Treaty in February 2026, with national phase entries
July 20, 2026

Cytosurge: Luba Greenwood joins Board of Directors

Cytosurge has appointed veteran biotech executive and investor Luba Greenwood, J.D., to its Board of Directors. With deep expertise across biotech, AI, and venture capital, Greenwood joins to accelerate Cytosurge’s US expansion and scale its Same-Cell Biology platform. By generating true causal data from living cells before and after intervention, Cytosurge aims to solve the critical data bottle
July 20, 2026

ten23 health expands excipient options for biologic drug development

ten23 health today highlights its research collaboration with dsm-firmenich, focused on expanding excipient options for parenteral biologic drug products. By combining complementary expertise, the collaboration aims to address one of the longstanding challenges in biologic formulation development: the limited availability of excipients suitable for injectable medicines.
July 15, 2026